Vinva Investment Management Ltd Decreases Stake in Hologic, Inc. (NASDAQ:HOLX)

Vinva Investment Management Ltd lessened its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 59.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,264 shares of the medical equipment provider's stock after selling 19,145 shares during the period. Vinva Investment Management Ltd's holdings in Hologic were worth $959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Swedbank AB lifted its position in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock valued at $157,788,000 after acquiring an additional 306,562 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Hologic by 22.2% during the third quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider's stock worth $469,000 after purchasing an additional 1,048 shares in the last quarter. OneDigital Investment Advisors LLC increased its position in shares of Hologic by 5.4% during the third quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider's stock worth $576,000 after purchasing an additional 360 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Hologic by 8.8% in the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider's stock worth $294,000 after purchasing an additional 291 shares in the last quarter. Finally, Pathstone Holdings LLC grew its stake in Hologic by 7.7% during the 3rd quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider's stock worth $2,422,000 after buying an additional 2,121 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup lowered their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Evercore ISI lowered their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Finally, Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Stock Performance

Hologic stock traded down $1.09 during mid-day trading on Tuesday, hitting $60.80. The company had a trading volume of 2,378,048 shares, compared to its average volume of 1,754,307. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.64 billion, a price-to-earnings ratio of 19.18, a P/E/G ratio of 2.14 and a beta of 0.97. The company's fifty day moving average is $65.89 and its 200-day moving average is $73.81. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.